The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389-96
   PubMed Web of Science ®Google Scholar
• Basch E, Somerfeild M, Beer T, Amercan Society of Clinical Oncology endorsement of the Cancer Care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007:25:5313-18
   PubMed Web of Science ®Google Scholar
• Stalhandske T, Eriksoo E, Sandberg B. A novel quinoline-3-carboxamide with interesting immunomodulatory activity. Int J Immunopharmacol 1982;4:336
   Web of Science ®Google Scholar
• Kalland T, Alm G, Stalhandshe T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 1985;134:3956-61
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 1986;46:3018-22
   PubMed Web of Science ®Google Scholar
• Nilsson BI. Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations. Cancer Detect Prev 1988;12:553-9
   PubMedGoogle Scholar
• Tarkowski A, Gunnarsson K, Nilsson A, Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum 1986;29:1405-9
   PubMed Web of Science ®Google Scholar
• Tarkowski A, Gunnarsson K, Stalhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology 1986;59:589-94
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Wake N, Coffey DS, Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 1982;42:2353-71
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10:26-7
   PubMed Web of Science ®Google Scholar
• Isaacs JT. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 1989;49:6290-4
   PubMed Web of Science ®Google Scholar
• Harning R, Szalay J. A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Vis Sci 1988;29:1505-10
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Lamb JC, Christensson PI, The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 1992;52:3022-8
   PubMed Web of Science ®Google Scholar
• Vukanovic J, Passaniti A, Hirata T, Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 1993;53:1833-7
   PubMed Web of Science ®Google Scholar
• Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71
   PubMedGoogle Scholar
• Borgstrom P, Torres Filho IP, Vajkoczy P, The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 1994;34:280-6
   PubMed Web of Science ®Google Scholar
• Lepisto J, Laato M, Niinikoski J, Stimulation of wound healing by the immunomodulator LS-2616 (Linomide). World J Surg 1994;18:818-20
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Torres Filho IP, Hartley-Asp B. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide. Anticancer Res 1995;15:719-28
   PubMed Web of Science ®Google Scholar
• Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-504
   PubMed Web of Science ®Google Scholar
• Gonzalo JA, Gonzalez-Garcia A, Kalland T, Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993;23:2372-4
   PubMed Web of Science ®Google Scholar
• Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995;55:3517-20
   PubMed Web of Science ®Google Scholar
• Bengtsson M, Simonsson B, Carlsson K, Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992;53:882-8
   PubMed Web of Science ®Google Scholar
• Pawinski A, van Oosterom AT, de Wit R, An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Eur J Cancer 1997;33:496-9
   PubMed Web of Science ®Google Scholar
• de Wit R, Pawinsky A, Stoter G, EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur J Cancer 1997;33:493-5
   PubMed Web of Science ®Google Scholar
• Karussis DM, Lehmann D, Slavin S, Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993;90:6400-4
   PubMed Web of Science ®Google Scholar
• Karussis DM, Meiner Z, Lehmann D, Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47:341-6
   PubMed Web of Science ®Google Scholar
• Andersen O, Lycke J, Tollesson PO, Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996;47:895-900
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Wolinsky JS, Lublin FD, Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000;54:1726-33
   PubMed Web of Science ®Google Scholar
• Tan IL, Lycklama a Nijeholt GJ, Polman CH, Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 2000;6:99-104
   PubMed Web of Science ®Google Scholar
• Joseph IB, Vukanovic J, Isaacs JT. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 1996;56:3404-8
   PubMed Web of Science ®Google Scholar
• Parenti A, Donnini S, Morbidelli L, The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br J Pharmacol 1996;119:619-21
   PubMed Web of Science ®Google Scholar
• Ziche M, Donnini S, Morbidelli L, Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer 1998;77:1123-9
   PubMed Web of Science ®Google Scholar
• Hartley-Asp B, Vukanovic J, Joseph IB, Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol 1997;158:902-7
   PubMed Web of Science ®Google Scholar
• Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997;57:1054-7
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Wienkers LC, Gunnarsson PO, Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica 2000;30:905-14
   PubMed Web of Science ®Google Scholar
• Jonsson S, Andersson G, Fex T, Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004;47:2075-88
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runstrom A, Ohlsson L, The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;130:163-72
   PubMed Web of Science ®Google Scholar
• Bjork P, Bjork A, Vogl T, Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97
   PubMed Web of Science ®Google Scholar
• Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009;18:985-9
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Pili R, Qian D, Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006;66:1768-78
   PubMed Web of Science ®Google Scholar
• Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007;67:790-7
   PubMed Web of Science ®Google Scholar
• Olsson A, Bjork A, Vallon-Christersson J, Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010;9:107
   PubMed Web of Science ®Google Scholar
• Bratt O, Haggman M, Ahlgren G, Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009;101:1233-40
   PubMed Web of Science ®Google Scholar
• Pili R, Haggman M, Stadler W, A randomized multicenter international phase II study of tasquinimod in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. (abstract 4510). J Clin Oncol 2010;28:75
   Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
   PubMed Web of Science ®Google Scholar
• Moeler BJ, Dewhirst MW. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 2004;3:1107-10
   PubMed Web of Science ®Google Scholar
• Colombel M, Filleur S, Fournier P, Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 2005;65:300-8
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Soydinc HO, Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced no small cells lung cancer. Cancer Chemother Pharmacol 2008;61:721-5
   PubMed Web of Science ®Google Scholar